IL2 and lupus nephritis: The Korean study testing haploidentical allogeneic BM-MSCs has progressed to a phase 2 trial for refractory lupus nephritis (NCT04835883), while a phase 3 RCT in China is comparing UC-MSC against low dose IL-2 as an add-on therapy to SOC immunosuppression (NCT05631717).